Exelixis News

Exelixis, Inc. Announces February 14 Webcast of Presentation at 14th Annual Biotechnology Industry Organization CEO & Investor Conference SOUTH SAN FRANCISCO, Calif.-- --Exelixis, Inc.

A A A' Product Pipeline Review A A A' H2 2011 - a new company profile report on companiesandmarkets.com Exelixis, Inc.

Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at the 14th annual BIO CEO & Investor Conference at 8:30 a.m. EST / 5:30 a.m. PST on Tuesday, February 14, 2012, in New York.

Shares of the following companies may have unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 7:40 a.m. in New York.

SOUTH SAN FRANCISCO, Calif. -- -- Exelixis, Inc. today announced that it plans to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering.

SOUTH SAN FRANCISCO, Calif.-- --Exelixis, Inc. today reported financial results for the fourth quarter and year ended December 31, 2011.

The top after-market NASDAQ gainers Wednesday were: Accuray Inc, support.com, Akamai Technologies, Cumberland Pharmaceuticals, Select Comfort Corp, Exelixis, FriendFinder Networks, Limelight Networks and American Capital Accuray Inc.

Good day, ladies and gentlemen, and welcome to the Q4 Exelixis Conference Call. My name is and I'll be your coordinator for today.

Exelixis, Inc. will release its fourth quarter and full year 2011 financial results on Wednesday, February 8, 2012, after the markets close.

Exelixis is starting to recuperate after last year's clash with the FDA regarding a registration trial for its lead agent, cabozantinib , in prostate cancer.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia SOUTH SAN FRANCISCO, Calif.-- --Exelixis, Inc.

Biotechnology companies are often a point of high risk and high reward for many traders since many of these companies success can greatly change depending on the news surrounding a single drug.

SOUTH SAN FRANCISCO, Calif.-- -- Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma patients participating in the ongoing phase 2 randomized discontinuation trial of cabozantinib.

SOUTH SAN FRANCISCO, Calif. -- -- Exelixis, Inc. today reported positive preliminary data from the cohort of hepatocellular carcinoma patients participating in the ongoing phase 2 randomized discontinuation trial of cabozantinib.